NRG1 and pancreatic ductal adenocarcinoma: Third, ERBB inhibition with erlotinib and pertuzumab was shown to result in clinical responses in two patients with NRG1-rearranged pancreatic ductal adenocarcinoma (PDAC) tumours, which is in line with our results and suggesting therapeutic options for tumours with aberrant ERBB receptor-mediated signalling arising from NRG1 activation [56].